Welcome to our dedicated page for Solventum Corporation news (Ticker: SOLV), a resource for investors and traders seeking the latest updates and insights on Solventum Corporation stock.
Solventum Corporation (NYSE: SOLV) generates a steady flow of news that reflects its role in the medical instruments and supplies sector and its focus on MedSurg, Dental Solutions and Health Information Systems. News about Solventum often highlights developments in advanced wound care, portfolio changes, capital allocation decisions and strategic initiatives intended to support long-term growth.
Recent announcements include agreements and completion of the acquisition of Acera Surgical, a bioscience company focused on fully engineered materials for regenerative wound care. These updates describe how Solventum is expanding its MedSurg portfolio into the synthetic tissue matrices technology space within acute care settings. Other news covers clinical and scientific developments, such as international consensus recommendations on the use of closed incision negative pressure therapy with reticulated open cell foam dressings, which relate directly to Solventum Prevena Therapy and its application across surgical specialties.
Investors and healthcare professionals following SOLV news will also see coverage of financial results, including quarterly earnings releases and guidance updates, as well as information about Solventum’s “Transform for the Future” initiative to reshape its cost structure and support innovation. Capital markets and balance sheet actions, such as cash tender offers for outstanding notes, the sale of the purification and filtration business to Thermo Fisher Scientific Inc., and the authorization of a share repurchase program, are reported through both press releases and SEC filings.
Additional news items may feature recognition of operational capabilities, such as the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative for supply chain strength in the MedSurg segment, and participation in healthcare investor conferences. By reviewing the SOLV news feed on a regular basis, readers can track how Solventum’s strategic decisions, clinical evidence, portfolio moves and financial performance are communicated to the market over time.
Solventum Corporation (NYSE: SOLV) has announced a secondary offering of 8,800,000 shares of its common stock, which will be sold entirely by 3M Company (the Selling Shareholder). The offering will be managed by Goldman Sachs & Co. LLC and BofA Securities, Inc. as underwriters.
The shares are being offered through Solventum's shelf registration statement on Form S-3, which became effective on August 13, 2025. Importantly, Solventum will not receive any proceeds from this offering as all shares are being sold by 3M Company. The offering will be conducted through a preliminary prospectus supplement and accompanying prospectus filed with the SEC.
Solventum (NYSE: SOLV) reported Q2 2025 financial results with sales increasing 3.9% to $2.2 billion and organic sales growth of 2.8%. The company achieved GAAP diluted EPS of $0.51 and adjusted diluted EPS of $1.69, marking five consecutive quarters of positive sales volume growth since implementing its transformation strategy.
Key financial metrics include operating cash flow of $169 million and free cash flow of $59 million. The company has increased its full-year 2025 guidance, projecting organic sales growth of 2.0% to 3.0% and adjusted EPS of $5.80 to $5.95. All segments showed positive organic growth, primarily driven by MedSurg and HIS segments.
Solventum (NYSE: SOLV) has scheduled its second quarter fiscal 2025 earnings release for Thursday, August 7, 2025, after U.S. market close. The company will host a webcast at 3:30 p.m. CDT / 4:30 p.m. EDT to discuss financial results and business updates.
Investors can access the webcast through the company's investor relations website at investors.solventum.com. The event will be available via phone with U.S. dial-in at +1 (800) 715-9871 and international dial-in at +1 (646) 307-1963, using Conference ID 6342275.
Following the event, a replay of the webcast, earnings release, presentation slides, and supplemental financial information will be accessible on Solventum's Investor Relations website.
Solventum (NYSE: SOLV) has announced its participation in the 2025 BofA Securities Health Care Conference. Company executives will engage in a fireside chat on Tuesday, May 13, 2025, at 2:20 p.m. PST in Las Vegas, NV. Investors and interested parties can access both live and archived replays of the presentation through the company's investor relations website at investors.solventum.com.
Solventum (NYSE: SOLV) has announced it will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, following the close of U.S. financial markets. The company will host a webcast at 3:30 p.m. CST / 4:30 p.m. EST to discuss the quarterly results and business updates.
The earnings webcast will be accessible through the company's investor relations website at investors.solventum.com. Participants can join via U.S. dial-in at +1 (800) 715-9871 or international dial-in at +1 (646) 307-1963 using Conference ID 6342275. Following the event, the webcast replay, earnings release, presentation slides, and supplemental financial information will be made available on Solventum's investor relations website.
Solventum (NYSE: SOLV) has announced a strategic partnership with SprintRay to revolutionize digital dentistry through same-day permanent restorations. The collaboration combines Solventum's expertise in dental composites and restorative materials with SprintRay's chairside 3D printing technology.
The R&D and commercialization agreement aims to develop the first permanent chairside 3D printed crown, along with inlays and onlays. This partnership promises to reduce patient visits, improve practice efficiency, and lower treatment costs while maintaining the quality expected from traditional laboratory-fabricated procedures.
The announcement aligns with Solventum's growth strategy and follows their recent launch of four new products in 2024, including 3D printed aligner attachments, fluoride treatment, multi-layer copolymer aligners, and universal restorative solutions. More details will be shared at the International Dental Show 2025 in Cologne, Germany.
Solventum (NYSE: SOLV) hosted its 2025 Investor Day to present its strategic priorities and long-range plan through 2028. CEO Bryan Hanson outlined the company's transformation following the sale of its Purification & Filtration business, focusing on Medical Surgical, Dental Solutions, and Health Information Systems segments.
The company announced key 2028 targets including:
- Organic sales growth of 4-5%
- Operating margins expansion to 23-25%
- EPS CAGR of 10% over 3 years
- Free cash flow conversion above 80%
Solventum's three-phase transformation plan includes:
- Stabilizing the business through culture and talent enhancement
- Enhancing strategic focus in high-potential markets
- Portfolio optimization through organic and inorganic growth opportunities